In addition to documenting the safety of this

approach, we found that patients treated with OK432-stimulated DCs displayed unique cytokine and chemokine Kinase Inhibitor Library high throughput profiles and, most importantly, experienced prolonged recurrence-free survival. Inclusion criteria were a radiological diagnosis of primary HCC by computed tomography (CT) angiography, hepatitis C virus (HCV)-related HCC, a Karnofsky score of ≥ 70%, an age of ≥ 20 years, informed consent and the following normal baseline haematological parameters (within 1 week before DC administration): haemoglobin ≥ 8·5 g/dl; white cell count ≥ 2000/µl; platelet count ≥ 50 000/µl; creatinine < 1·5 mg/dl and liver damage A or B [23]. Exclusion criteria included severe cardiac, renal, pulmonary, haematological or other

systemic disease associated with a discontinuation risk; human immunodeficiency virus (HIV) infection; prior history of other malignancies; history of surgery, chemotherapy or radiation therapy within 4 weeks; immunological disorders including splenectomy and radiation to the spleen; corticosteroid or anti-histamine therapy; current lactation; pregnancy; history of organ transplantation; or difficulty in follow-up. Thirteen patients (four women and nine men) presenting at Kanazawa www.selleckchem.com/products/sorafenib.html University Hospital between March 2004 and June 2006 were enrolled into the study, with an age range from 56 to Tryptophan synthase 83 years (Table 1). Patients with verified radiological diagnoses of HCC stage II or more were eligible and enrolled in this study. In addition, a group of 22 historical controls (nine women and 13 men) treated with TAE without DC administration between July 2000 and September 2007 was included in this study. All patients received RFA therapy to increase the locoregional effects 1 week later [24]. They underwent ultrasound, computed tomography (CT) scan or magnetic resonance imaging (MRI) of the abdomen about 1 month after treatment and at a minimum of

once every 3 months thereafter, and tumour recurrences were followed for up to 360 days. The Institutional Review Board reviewed and approved the study protocol. This study complied with ethical standards outlined in the Declaration of Helsinki. Adverse events were monitored for 1 month after the DC infusion in terms of fever, vomiting, abdominal pain, encephalopathy, myalgia, ascites, gastrointestinal disorder, bleeding, hepatic abscess and autoimmune diseases. DCs were generated from blood monocyte precursors, as reported previously [25]. Briefly, peripheral blood mononuclear cells (PBMCs) were isolated by centrifugation in LymphoprepTM Tubes (Nycomed, Roskilde, Denmark). For generating DCs, PBMCs were plated in six-well tissue culture dishes (Costar, Cambridge, MA, USA) at 1·4 × 107 cells in 2 ml per well and allowed to adhere to plastic for 2 h.